Antibody Directed Enzyme Prodrug Therapy (ADEPT) and Related Approaches for Anticancer Therapy

Author: Jung M.

Source: Mini Reviews in Medicinal Chemistry, Volume 1, Number 4, November 2001 , pp. 399-407(12)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

In antibody directed enzyme prodrug therapy (ADEPT) an antibody bound enzyme is targeted to tumor cells. This allows for selective activation of a nontoxic prodrug to a cytotoxic agent at the tumor site for cancer therapy. Site-selective prodrug activation results in reduced side effects in remote tissue. This article reviews ADEPT with emphasis on the chemical viewpoint and recent developments.

Keywords: Antibody Directed Enzyme Prodrug Therapy; ADEPT; Anticancer Therapy; Alkaline Phosphatase; Amino Peptidases; Aryl Sulfatase; Carboxylesterase; Carboxypeptidase A; Carboxypeptidase G2 (CpG2); Cytosine Deaminase

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389557013406747

Publication date: 2001-11-01

More about this publication?

The aim of Mini-Reviews in Medicinal Chemistry is to publish short reviews on the important recent developments in medicinal chemistry and allied disciplines.

The scope of Mini-Reviews in Medicinal Chemistry will cover all areas of medicinal chemistry including developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, drug targets, and natural product research and structure-activity relationship studies.

Mini-Reviews in Medicinal Chemistry is an essential journal for every medicinal and pharmaceutical chemist who wishes to be kept informed and up-to-date with the latest and most important developments.